SCHEMBL321038

SCHEMBL321038

COc1c(C)c(C(=O)c2ccc3[nH]cc(C(=O)O)c(=O)c3c2)n2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.42
▸ HSD17B10 Q99714 6/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ POLB P06746 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ HPGD P15428 5/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HTT P42858 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PTPN22 Q9Y2R2 1/20 0.40
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12505747 0.90 POLB (0.42) KDM4EHSD17B10MEN1KMT2APOLB
SCHEMBL321292 0.89 ALDH1A1 (0.52) KDM4EHSD17B10MEN1KMT2AHPGD
SCHEMBL321473 0.83 HTT (0.41) KDM4EHSD17B10MEN1KMT2APOLB
SCHEMBL17004136 0.83 HTT (0.39) KDM4EHSD17B10MEN1KMT2APOLB
SCHEMBL320775 0.82 POLB (0.41) KDM4EHSD17B10KMT2APOLBHPGD
SCHEMBL145931 0.78 HTT (0.45) MEN1KMT2ACYP2C9CYP1A2HPGD
SCHEMBL14916185 0.78 HTT (0.39) KDM4EMEN1KMT2ACYP2C9CYP1A2
SCHEMBL3954660 0.77 HTT (0.44) MEN1KMT2ACYP2C9CYP1A2HPGD
SCHEMBL14916577 0.77 BRD4 (0.40) KDM4EMEN1KMT2ACYP2C9CYP1A2
SCHEMBL321863 0.77 CA12 (0.41) MEN1KMT2AALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 KDM4E 633/4885HSD17B10 4071/4885MEN1 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback